relapses

Study finds altered gut bacteria in people with relapsing NMOSD

The composition of bacteria in the gut is altered in neuromyelitis optica spectrum disorder (NMOSD) patients experiencing disease relapses compared with healthy people in the same household, a study reports. Following treatment, however, the gut bacterial profiles of NMOSD patients in remission resembled those of healthy people. “The…

AAN2024: No relapses with Ultomiris after more than 2.5 years

None of the neuromyelitis optica spectrum disorder (NMOSD) patients in the Phase 3 CHAMPION-NMOSD clinical trial have had a disease relapse while on Ultomiris (ravulizumab-cwvz) treatment for a median of more than 2.5 years. These findings were shared by Sean Pittock, MD, the trial’s principal investigator, at the…

Tocilizumab found to be effective, safe for NMOSD: Meta-analysis

Tocilizumab, an anti-inflammatory medication used off-label for neuromyelitis optica spectrum disorder (NMOSD), can help prevent relapses (flare-ups) and ease disability while being generally safe, according to a meta-analysis. The study, “Tocilizumab treatment in neuromyelitis optica spectrum disorders: Updated meta-analysis of efficacy and safety,” was published in the journal…

Antinuclear antibodies linked to more severe NMOSD

The presence of certain self-reactive antibodies called antinuclear antibodies (ANAs) in the blood is associated with worse disability and more severe relapses in people with neuromyelitis optica spectrum disorder (NMOSD), according to a study from China. “Our results suggest that ANA seems to be more associated with severe disease…

Treatment Changes More Common in NMOSD Patients with Relapses

People with neuromyelitis optica spectrum disorder (NMOSD) who experience relapses are three times more likely to change their treatment regimen than those who have no relapses, a study found. Researchers also observed that people who experienced optic neuritis with or without brain symptoms, those with shorter disease duration, and…